Lv4
450 积分 2023-09-03 加入
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study
12小时前
已完结
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
2个月前
已完结
Genome-wide association studies reconstructing chronic kidney disease
8个月前
已完结
Association of Preterm Birth with Adverse Glomerular Disease Outcomes in Children and Adults
8个月前
已关闭
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events
9个月前
已完结
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
9个月前
已完结
Current status and future trends of the global burden of MASLD
9个月前
已完结
Obesity and the kidney: mechanistic links and therapeutic advances
9个月前
已完结
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease
10个月前
已完结
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
10个月前
已完结
皖公网安备34019202002308
